Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhopressa for Corneal Edema in Fuchs Dystrophy
NCT04051463Phase 3Completed
- Sponsor
- Price Vision Group
- Start
- Aug 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of netarsudil in Fuchs endothelial corneal dystrophy (FECD), sponsored by Price Vision Group. Started Aug 2019; status: completed.
02
Drugs
netarsudil
03
Conditions
Fuchs endothelial corneal dystrophy (FECD)
Beyond the preview
Go deeper on NCT04051463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051463.